Interleukin-17A promotes osteoclastogenesis in chronic gouty arthritis

doi:10.16352/j.issn.1001-6325.2025.12.1608

Abstract

Abstract: Objective Chronic gouty arthritis (CGA) can lead to severe bone erosion resulting in joint destruction, which significantly decreases the life quality and prognosis of CGA patients. Osteoclasts play an important role in this course. We aim to investigate the effect of interleukin-17A (IL-17A) on osteoclast formation in vitro in patients with chronic gouty arthritis (CGA) and its potential mechanism. Methods Osteoclasts induced in vitro from peripheral blood mononuclear cells (PBMC) of healthy controls (HC) and CGA patients were studied. CGA-derived osteoclasts were divided into four groups: untreated group, IL-17A-treated group, carbonyl cyanide 3-chlorophenylhydrazone (CCCP) group, and mitochondrial division inhibitor-1 (Mdivi-1) group. Tartrate-resistant acid phosphatase (TRAP) staining was used to observe and compare osteoclastogenesis between HC and the untreated group. Western blot was performed to detect mitophagy levels and the expression of key osteoclast differentiation factors. Results Compared with healthy controls, CGA patients showed higher osteoclastogenesis(P＜0.01). Compared with the untreated group, the IL-17A-treated group showed up-regulated expression of key osteoclast transcription factors and decreased mitophagy levels (P＜0.05). Intervention with 10 nmol/L and 15 nmol/L Mdivi-1 significantly promoted the expression of key osteoclast transcription factors (P＜0.01). Conclusions IL-17A promotes osteoclast formation in vitro in CGA patients, and its mechanism may be related to decreased mitophagy levels.

Key words: gout, IL-17A, osteoclast, mitophagy, bone erosion

CLC Number:

R593.9

WANG Yibo, DI Hong, ZHANG Xiaohan, ZHANG Yun, ZENG Xuejun. Interleukin-17A promotes osteoclastogenesis in chronic gouty arthritis[J]. Basic & Clinical Medicine, 2025, 45(12): 1608-1613.

References

[1] Zhou X, Liu K, Shi C, et al. Estimation of the spatial pattern of gout prevalence across China by wastewater-based epidemiology[J]. Sci Total Environ, 2024, 924: 171565. doi: 10.1007/s11926-014-0492-x.
[2] Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis[J]. Ann Rheum Dis, 2010, 69: 1907-1912.
[3] McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies[J]. Nat Rev Rheumatol, 2012, 8: 173-181.
[4] Miossec P. Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting[J]. Cell Mol Immunol, 2021, 18: 860-865.
[5] 韩欣欣. 痛风性关节炎临床及发病机制研究[D]. 北京: 北京协和医学院, 2021: 38-101.
[6] 白煜佳. 痛风性关节炎患者血清及组织中Il-17水平研究[D]. 北京: 北京协和医学院, 2015: 44-60.
[7] 狄虹. IL-17参与痛风性关节炎发病机制研究及相关药物初探 [D]. 北京: 北京协和医学院, 2024: 29-60.
[8] Chhana A, Dalbeth N. The gouty tophus: a review[J]. Curr Rheumatol Rep, 2015, 17: 19. doi: 10.1007/s11926-014-0492-x.
[9] Yan C, Shi Y, Yuan L, et al. Mitochondrial quality control and its role in osteoporosis[J]. Front Endocrinol, 2023, 14: 1077058. doi: 10.1007/s11926-014-0492-x.
[10] Neogi T, Jansen T L, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015, 74: 1789-1798.
[11] Dalbeth N, Smith T, Nicolson B, et al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells[J]. Arthritis Rheum, 2008, 58: 1854-1865.
[12] Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease[J]. Nat Rev Immunol, 2019, 19: 626-642.
[13] Zeng Z, Zhou X, Wang Y, et al. Mitophagy-A new target of bone disease[J]. Biomolecules, 2022, 12:1420. doi: 10.3390/biom12101420.
[14] Jang J S, Hong S J, Mo S, et al. PINK1 restrains periodontitis-induced bone loss by preventing osteoclast mitophagy impairment[J]. Redox Biol, 2024, 69: 103023. doi: 10.1016/j.redox.2023.103023.
[15] Liao H, Chang X, Gao L, et al. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer[J]. J Transl Med, 2023, 21: 828. doi: 10.1186/s12967-023-04365-3.